162 related articles for article (PubMed ID: 29927060)
1. Tertiary-Amine-Based Inhibitors of the Astacin Protease Meprin α.
Tan K; Jäger C; Schlenzig D; Schilling S; Buchholz M; Ramsbeck D
ChemMedChem; 2018 Aug; 13(16):1619-1624. PubMed ID: 29927060
[TBL] [Abstract][Full Text] [Related]
2. First insight into structure-activity relationships of selective meprin β inhibitors.
Ramsbeck D; Hamann A; Schlenzig D; Schilling S; Buchholz M
Bioorg Med Chem Lett; 2017 Jun; 27(11):2428-2431. PubMed ID: 28408220
[TBL] [Abstract][Full Text] [Related]
3. Heteroaromatic Inhibitors of the Astacin Proteinases Meprin α, Meprin β and Ovastacin Discovered by a Scaffold-Hopping Approach.
Tan K; Jäger C; Körschgen H; Geissler S; Schlenzig D; Buchholz M; Stöcker W; Ramsbeck D
ChemMedChem; 2021 Mar; 16(6):976-988. PubMed ID: 33369214
[TBL] [Abstract][Full Text] [Related]
4. Structure and Dynamics of Meprin β in Complex with a Hydroxamate-Based Inhibitor.
Linnert M; Fritz C; Jäger C; Schlenzig D; Ramsbeck D; Kleinschmidt M; Wermann M; Demuth HU; Parthier C; Schilling S
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073350
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Design, Synthesis, and Characterization of Next-Generation Meprin β Inhibitors.
Ramsbeck D; Hamann A; Richter G; Schlenzig D; Geissler S; Nykiel V; Cynis H; Schilling S; Buchholz M
J Med Chem; 2018 May; 61(10):4578-4592. PubMed ID: 29694039
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
[TBL] [Abstract][Full Text] [Related]
7. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors.
Kruse MN; Becker C; Lottaz D; Köhler D; Yiallouros I; Krell HW; Sterchi EE; Stöcker W
Biochem J; 2004 Mar; 378(Pt 2):383-9. PubMed ID: 14594449
[TBL] [Abstract][Full Text] [Related]
8. A kinetic comparison of the homologous proteases astacin and meprin A.
Wolz RL
Arch Biochem Biophys; 1994 Apr; 310(1):144-51. PubMed ID: 8161197
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling coupled with molecular dynamic simulation approach to identify new leads for meprin-β metalloprotease.
Chaudhuri A; Hudait N; Chakraborty SS
Comput Biol Chem; 2019 Jun; 80():292-306. PubMed ID: 31054542
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
Hanessian S; MacKay DB; Moitessier N
J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
[TBL] [Abstract][Full Text] [Related]
13. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
Hanessian S; Moitessier N; Gauchet C; Viau M
J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
[TBL] [Abstract][Full Text] [Related]
14. News from an ancient world: two novel astacin metalloproteases from the horseshoe crab.
Becker-Pauly C; Bruns BC; Damm O; Schütte A; Hammouti K; Burmester T; Stöcker W
J Mol Biol; 2009 Jan; 385(1):236-48. PubMed ID: 18996129
[TBL] [Abstract][Full Text] [Related]
15. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
16. Development of piperazine-based hydroxamic acid inhibitors against falcilysin, an essential malarial protease.
Chance JP; Fejzic H; Hernandez O; Istvan ES; Andaya A; Maslov N; Aispuro R; Crisanto T; Nguyen H; Vidal B; Serrano W; Kuwahara B; Pugne Andanado C; Goldberg DE; Mallari JP
Bioorg Med Chem Lett; 2018 Jun; 28(10):1846-1848. PubMed ID: 29691139
[TBL] [Abstract][Full Text] [Related]
17. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
[TBL] [Abstract][Full Text] [Related]
18. Insights from Analysis of Binding Sites of Human Meprins: Screening of Inhibitors by Molecular Dynamics Simulation Study.
Chaudhuri A; Bera AK; Sarkar I; Chakraborty S
Comb Chem High Throughput Screen; 2016; 19(3):246-58. PubMed ID: 26875789
[TBL] [Abstract][Full Text] [Related]
19. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
